ライフサイエンスコーパス: drug resistance

1 mechanisms involved in stress tolerance and drug resistance.

2 ddress the multitude of challenges in cancer drug resistance.

3 ng-term outcomes and the risk of propagating drug resistance.

4 ore rebound occurred due to the emergence of drug resistance.

5 mostly ended up promoting the development of drug resistance.

6 y and clinically relevant phenotypes such as drug resistance.

7 modal antiviral agents are needed to prevent drug resistance.

8 nitoring (MRM), as they play a vital role in drug resistance.

9 ced look at the problems of drug potency and drug resistance.

10 y temporary due to the emergence of acquired drug resistance.

11 forts but is complicated by the emergence of drug resistance.

12 ed to incomplete medication adherence and/or drug resistance.

13 A5 is upregulated in cancer, contributing to drug resistance.

14 culture a mixture of GBM and MG and evaluate drug resistance.

15 eutic approach to fight transporter-mediated drug resistance.

16 ORC1 signaling as an actionable mechanism of drug resistance.

17 n the potential for the development of viral drug resistance.

18 ring the same genetic lesion and pathways of drug resistance.

19 in key receptor tyrosine kinases, that drive drug resistance.

20 reatment and delay emergence of antimalarial drug resistance.

21 paradigm shift in efforts to overcome cancer drug resistance.

22 establishes necrocytosis as a mechanism for drug resistance.

23 logical monitoring has driven increasing HIV drug resistance.

24 Most concerning are the reports of multidrug drug resistance.

25 nd identifies novel pathways associated with drug resistance.

26 itors, most patients eventually relapse with drug resistance.

27 number expansion of genes that contribute to drug resistance.

28 pathways to thwart the expected emergence of drug resistance.

29 ng tumor microenvironment or contributing to drug resistance.

30 the efficacy of the therapies and modulating drug resistance.

31 ng in areas with artemisinin and ACT partner-drug resistance.

32 its effectiveness in combating the advent of drug resistance.

33 due to mechanism (s) driving metastasis and drug resistance.

34 tructured 5'-UTRs and has been implicated in drug resistance.

35 , SWI/SNF-specific gene deletion resulted in drug resistance.

36 g reduction in viraemia, without evidence of drug resistance.

37 combination therapy to prevent the onset of drug resistance.

38 of global dimension, worsened by increasing drug resistance.

39 n several cancers and has been implicated in drug resistance.

40 activation and highlights the challenges of drug resistance.

41 rvoir for ongoing transmission and potential drug resistance.

42 t that is required for tumor progression and drug resistance.

43 lular glutamate residue that is critical for drug resistance.

44 ment, thus contributing to the rapid rise in drug resistance.

45 role in cancer progression, metastasis, and drug resistance.

46 increases EGFR signaling and contributes to drug resistance.

47 overy to characterization of genes mediating drug resistance.

48 and co-delivery of drugs and genes to combat drug resistance.

49 mental health issues are at higher risk for drug resistance.

50 ts (ROCK inhibitor) to overcome BMME-induced drug resistance.

51 d at the same time reduce the development of drug resistance.

52 th the effects of selection for antimalarial drug resistance.

53 BRAF(V600E)-driven melanoma progression and drug resistance.

54 bility, pathogenesis, immune modulation, and drug resistance.

55 ced HER2(+) breast cancer ultimately develop drug resistance.

56 f A. fumigatus biofilms increases antifungal drug resistance.

57 of cancer spread but instead associated with drug resistance.

58 ofilm physiology and contemporary antifungal drug resistance.

59 enesis, wound healing, cancer metastasis and drug resistance.

60 les and Pseudomonas aeruginosa, enriched for drug resistance.

61 nt and have been linked to poor outcomes and drug resistance.

62 iral clearance, with no evidence of acquired drug resistance.

63 splatin, whereas its overexpression promotes drug resistance.

64 existing mechanisms associated with acquired drug resistance.

65 the intratumoral microenvironment and cancer drug resistance.

66 mutations in drug target genes and confirmed drug resistance.

67 abolic growth and promote tumorigenicity and drug resistance.

68 ps (MDR-TB and XDR-TB) based on two types of drug resistance.

69 mited owing to on-target toxicities(5-7) and drug resistance(8-10).

70 anscriptomic data sets and new data modeling drug-resistance acquisition in leukemic T cells.

71 d role in promoting survival, virulence, and drug resistance across diverse pathogenic fungal species

72 fy residues that mediate kinase activity and drug resistance across the kinome.

73 human immunodeficiency virus type 1 (HIV-1) drug resistance (ADR) has fallen dramatically since intr

74 SHP2 signaling was recently linked to drug resistance against cancer medications such as MEK a

75 , describe their ability to reverse existing drug resistance against clinically relevant antibiotics.

76 Here, we report direct evidence of multi-drug resistance among foals treated with MaR.

77 ss the three countries, there was widespread drug resistance among S. Typhi, including FQ non-suscept

78 The surveillance of drug resistance among tuberculosis (TB) patients is cent

79 Emergence of antimicrobial drug-resistance amongst food-borne pathogens has led to

80 varian cancer (HGSOC) and is associated with drug resistance and a poor prognosis(1).

81 r therapeutic strategies aimed at overcoming drug resistance and abrogating metastasis.

82 lysosomes during the development of acquired drug resistance and an improved understanding of target

83 The recent rise in antibiotic drug resistance and biofilm formation by microorganisms

84 o development, oncogenesis, the emergence of drug resistance and cell signaling dynamics.

85 generalizable activation site that mediates drug resistance and confirm its impact in BRAF, EGFR, HE

86 Drug resistance and dose-limiting toxicities are signifi

87 Our model neglects drug resistance and focuses on the country-level epidemi

88 Mechanisms leading to acquired drug resistance and future challenges in the field are a

89 is, immune suppression, invasion, migration, drug resistance and GBM recurrence.

90 r patients with STAT3 inhibitors often meets drug resistance and heterogeneous response.

91 f breast cancer characterized by metastasis, drug resistance and high rates of recurrence.

92 latency, decreasing the risk for mutational drug resistance and increasing generation time, but pote

93 the role of microRNAs (miRNAs) in regulating drug resistance and leukemic stem cell (LSC) fate, we pe

94 ic variability that accelerates selection of drug resistance and limits the efficacy of most vaccines

95 ctivation upon genotoxic treatments promotes drug resistance and metastasis in breast cancers.

96 rowth factor signaling during EMT-associated drug resistance and metastasis.

97 country World Bank income classification and drug resistance and propensity-score matching on age, se

98 nism for the rapid acquisition of antifungal drug resistance and provide genomic evidence for the het

99 ate a biomathematical framework encompassing drug resistance and radiobiology to simulate patterns of

100 s) have the ability to self-renew and induce drug resistance and recurrence in colorectal cancer (CRC

101 Ultimately, heterogeneity contributes to drug resistance and relapse after therapy, resulting in

102 amation, and therefore likely contributed to drug resistance and relapse in these cases.

103 seling while delaying ART switch may promote drug resistance and should be reconsidered.

104 Overcoming drug resistance and targeting cancer stem cells remain c

105 With increasing drug resistance and the absence of a clinically availabl

106 ntiretroviral therapies, drawbacks including drug resistance and the failure to eradicate infection h

107 so plays a regulatory function in antibiotic drug resistance and the immune response of cells against

108 mprove patient care and prevent emergence of drug resistance and treatment failure.

109 and molecular profiles, which contributes to drug resistance and treatment failure.

110 failure upon standard care due to antiviral drug resistance and treatment-limiting side effects.

111 abiotic surfaces, and an important cause of drug resistance and virulence.

112 We investigated ART failure, drug resistance, and early mortality among patients with

113 ing cell proliferation, migration, invasion, drug resistance, and epithelial-mesenchymal transition (

114 to optimise the therapeutic index, overcome drug resistance, and establish combination therapies.

115 a range of mutations associated with cancer, drug resistance, and genetic disorders.

116 nodeficiency virus, extensive antiretroviral drug resistance, and high self-reported adherence rates,

117 myeloma (MM) promote tumor growth, survival, drug resistance, and immune suppression.

118 hat may be involved in cancer proliferation, drug resistance, and metastasis.

119 cures" in NB models of intrinsic or acquired drug resistance, and models of high-risk sarcomas, warra

120 of lncRNAs in exosomes and their function in drug resistance, and therapeutic importance of exosomal

121 nt of an HIV vaccine, as well as diagnostic, drug resistance, and viral load assays, which are essent

122 e to HIV vaccine development and diagnostic, drug resistance, and viral load assays.

123 mes in persons who have more-extensive HIV-1 drug resistance are uncertain.

124 nature of parasite genotypes associated with drug resistance as well as the frequency of the Pfhrp2/3

125 of targeting enhancer plasticity to overcome drug resistance associated with epigenetic therapies.

126 interest such as orthologs of P. falciparum drug resistance-associated loci (Pfdhfr, Pfdhps, Pfcrt,

127 ficiency virus (HIV) molecular diversity and drug resistance-associated mutations (DRMs) among treatm

128 opulation-based Sanger sequencing, and major drug resistance-associated mutations (RAM) were identifi

129 ing diagnostics, environmental surveillance, drug resistance, burden of disease, and vaccines, as wel

130 driver may include not only a mechanism for drug resistance, but changes in tumor oncogenic potentia

131 ress signals such as targeted inhibitors and drug resistance, but most therapy-resistant preclinical

132 DIT is not only a mechanism of inherited drug resistance, but proliferating DIT cells can produce

133 tion disrupted compound binding and provided drug resistance, but this was at the cost of viral fitne

134 ver modulates the speed of selection against drug resistance by amplifying the effects of competition

135 nd potential strategies for circumvention of drug resistance by modulation of microRNA levels.

136 erapies and inevitable emergence of acquired drug resistance (chemo and endocrine) as well as radio r

137 <=10 um) from 452 patients with TB (227 with drug resistance), compared clinical characteristics, and

138 heir efficacy can be compromised by acquired drug resistance conferred by EGFR-mutant variants.

139 circulating MDR Mtb strains and what impact drug-resistance-conferring mutations have on immunometab

140 Aggregated drug resistance data reported to WHO from either routine

141 tance testing by ultra-deep sequencing, with drug resistance defined as intermediate or high-level re

142 series of cellular assays for metastasis and drug resistance demonstrated efficient SHP2 blockade.

143 re still patients at risk of newly acquiring drug resistance despite having access to cART.

144 stitution, CMV viral load, and the potential drug resistance detected at the time of initiation of an

145 th known mechanisms of reactions involved in drug resistance (drug extrusion, drug degradation, and D

146 ns, including the identification of acquired drug resistance during treatments.

147 bition of both EGFR and STAT3 might overcome drug resistance encountered during treatment with single

148 in other puzzling spatiotemporal features of drug-resistance epidemiology that have received less att

149 cials and doctors need to understand whether drug resistance exists in the parasite population, as we

150 imental analysis of the mechanism underlying drug resistance for three major resistance mutations (G2

151 ylobacter species clusters carrying multiple drug resistance genes that segregated with these isolate

152 Antimalarial drug resistance has historically arisen through converge

153 Drug resistance has profoundly limited the success of ca

154 Emerging HIV drug resistance (HIVDR) could jeopardize the success of

155 HIV drug resistance (HIVDR) is a barrier to sustained virolo

156 a trending new standard for genotypic HIV-1 drug resistance (HIVDR) testing.

157 re susceptible to high rates of acquired HIV drug resistance (HIVDR), but few studies include childre

158 Combination chemotherapy could overcome drug resistance; however, GBM's location behind the bloo

159 ing can be used to monitor the spread of HIV drug resistance, identify appropriate antiretroviral reg

160 Primary and acquired drug resistance imposes a major threat to achieving opti

161 Drug resistance in both cell lines was reversible upon i

162 effect and deal with the occurrence of multi-drug resistance in cancer treatment.

163 cellular reprogramming, and the emergence of drug resistance in cancer.

164 n evolutionary traps that selectively target drug resistance in cancer.

165 erstanding the complex mechanisms underlying drug resistance in cancers.

166 for their anticancer activity and impact on drug resistance in comparison to metal-free thiosemicarb

167 The model accounted for drug resistance in determining viral suppression, with c

168 Acquired drug resistance in epidermal growth factor receptor (EGF

169 stic cells and extracellular matrix (ECM) on drug resistance in glioblastoma (GBM) cells.

170 The emergence of drug resistance in Helicobacter pylori has resulted in a

171 Antiviral drug resistance in influenza infections has been a major

172 Thus, HASPIN inhibition may overcome drug resistance in melanoma, modulate the immune environ

173 tively synergized with ampicillin to reverse drug resistance in multiple MRSA strains.

174 opment of new strategies for surveillance of drug resistance in other populations.

175 new, rapid spectroscopic approach to detect drug resistance in pathogens, based on their early posit

176 Artemisinin and partner-drug resistance in Plasmodium falciparum are major threa

177 rgence and spread of artemisinin and partner drug resistance in Plasmodium falciparum in the Greater

178 The recurrent emergence of drug resistance in Plasmodium falciparum increases the u

179 done to unravel the genetic underpinnings of drug resistance in Plasmodium falciparum.

180 results indicate that MaR use promotes multi-drug resistance in R. equi and commensals that are shed

181 ritical mechanism of acquired antimetabolite drug resistance in relapsed childhood ALL.

182 ges in AMR to inform policies and to monitor drug resistance in S. Paratyphi, for which there is no v

183 clear localization of Polkappa might prevent drug resistance in some cancer cells.

184 We adapted the Modeling Antiretroviral drug Resistance In South Africa (MARISA) model, an epide

185 idy correlates with slowed proliferation and drug resistance in the Cancer Cell Line Encyclopedia (CC

186 ial adaptation and promotes pathogenesis and drug resistance in the human host.

187 MEK inhibition and was again up-regulated on drug resistance in vitro and in vivo.

188 e signals provides mechanistic insights into drug resistance, increases the predictive power for drug

189 such as treatment response and emergence of drug resistance: inference based on genomic, transcripto

190 temisinin combination therapy, the threat of drug resistance is a constant obstacle to sustainable ma

191 Drug resistance is a critical problem limiting effective

192 The emergence of drug resistance is a major obstacle for the success of t

193 HIV drug resistance is a major threat to achieving long-term

194 mechanistic principles governing antifungal drug resistance is fundamental for the development of no

195 reatment options are limited, and antifungal drug resistance is increasing.

196 tality rates are still unacceptably high and drug resistance is increasing.

197 However, the mechanism of drug resistance is not fully understood.

198 the CHK1 kinase are advancing in the clinic, drug resistance is rapidly emerging.

199 iciency and substrate specificity leading to drug resistance is unclear.

200 Cancer, a disease that is prone to drug resistance, is in principle susceptible to such tra

201 g the looming crisis of widespread microbial drug resistance it is an attractive target.

202 Ms found in the study exacerbate the primary drug resistance landscape, which highlight the necessity

203 epistasis are prevalent in the antimalarial drug-resistance landscape.

204 (median HE = 0.7) were selected along with 7 drug resistance loci.

205 Recovery of isolates with multi-drug resistance (MDR) genotypes was lower from McC + CTX

206 od, where the tested strains exhibited multi-drug resistance (MDR) to amoxicillin, cefotaxime, tetrac

207 ncreases the urgency to genetically validate drug resistance mechanisms and identify new targets.

208 nderstanding of fungal cell architecture and drug resistance mechanisms.

209 llance, and a comprehensive understanding of drug resistance mechanisms.

210 ug imatinib binds enabled the elucidation of drug-resistance mechanisms.

211 Drug resistance mediated by clonal evolution is arguably

212 Moreover, we demonstrate that drug resistance mediated by dynamic oxygen gradients, fo

213 Population genetic analyses of the key drug resistance-mediating polymorphisms were analyzed in

214 erspective on the molecular underpinnings of drug resistance might help formulate novel combination t

215 highlight the necessity of timely genotypic drug resistance monitoring and molecular surveillance of

216 Overall, 80.6% (58/72) had at least one drug resistance mutation (DRM).

217 IV-1 isolates (2.4%, 4/168) had surveillance drug-resistance mutation (SDRM), including 3 nonnucleosi

218 Furthermore, we explored the acquisition of drug resistance mutations (DRMs) among SD arm nonlinkers

219 Point mutation assays targeting priority drug resistance mutations (DRMs) are being evaluated to

220 id (CSF) and plasma may result in discordant drug resistance mutations (DRMs) in the compartments.

221 oth the identity and relative proportions of drug resistance mutations (DRMs) on individual HIV-1 pol

222 owever the relative contributions of pre-ART drug resistance mutations (DRMs) vs nonadherence in the

223 ir antiretroviral (ARV) susceptibilities and drug resistance mutations (DRMs).

224 ants, World Health Organization surveillance drug resistance mutations (SDRMs) were noted.

225 therapeutics for EGFR mutant NSCLC; however, drug resistance mutations limit their success.

226 despite adherence to ART and the absence of drug resistance mutations.

227 load estimates and quantitative summaries of drug resistance mutations; it also exploits information

228 infection, previous literature examining how drug-resistance mutations alter Mtb physiology and diffe

229 multiplexed identification of dozens of HIV drug-resistance mutations.

230 eting chemotherapeutics and reduce cytotoxic drug resistance.New generation antibiotics such as biofi

231 Despite the role of EMT in metastasis and drug resistance, no standardized assessment of EMT pheno

232 amework for creating avenues to overcome the drug resistance of ferroptosis activators.

233 ctive cell envelope contributes to the broad drug resistance of the nosocomial pathogen Acinetobacter

234 quires an active EPHB4 pathway that supports drug resistance of this tumor type.

235 enetic modifications are closely involved in drug resistance of tumor cells.

236 f TGF-beta might be related to the increased drug-resistance of cancer cells.

237 P53 mutations are responsible for drug-resistance of tumour cells which impacts on the eff

238 Multidrug transporters can confer drug resistance on cells by extruding structurally unrel

239 status, antiviral therapy, and emergence of drug resistance on viral shedding in children infected w

240 eatment difficulties in some patients due to drug resistance or intolerability.

241 amplification in human cancers with acquired drug resistance or oncogene amplifications.

242 novel genetic variants in causing a disease, drug resistance, or another specific trait.

243 proliferation pathways accomplish a similar drug resistance outcome.

244 lencing by the SETD5 complex regulates known drug resistance pathways to reprogram cellular responses

245 stigated associated phenotypic and genotypic drug resistance patterns.

246 ts have recommended testing for pretreatment drug resistance (PDR) before antiretroviral therapy (ART

247 le is known about the impact of pretreatment drug resistance (PDR) on the efficacy of second generati

248 proaches to reduce the spread of these multi-drug-resistance plasmids.

249 esenchymal features has been associated with drug resistance, poor prognosis, and disease relapse in

250 een applied to the detection and analysis of drug-resistance profile of Mycobacterium tuberculosis co

251 Human immunodeficiency virus (HIV) drug resistance profiles are needed to optimize individu

252 Computational techniques for predicting drug resistance profiles from genomic data can accelerat

253 Highly divergent HIV drug resistance profiles were observed among candidates

254 treated with targeted antiendocrine agents, drug resistance remains a significant issue, with almost

255 transition (EMT) for cancer progression and drug resistance remains to be fully elucidated in the cl

256 ertheless, its specific mechanism in driving drug-resistance remains unclear.

257 Of 237 patients with HIV drug resistance results available, 195 (82%) had resista

258 that regulate fungal virulence or antifungal drug resistance, such as regulators of fungal stress res

259 l monitoring with molecular epidemiology and drug resistance surveillance in low-income settings.

260 d for optimal use of new drugs, the need for drug resistance surveillance, and a comprehensive unders

261 ("baseline genotype") to detect transmitted drug resistance (TDR) to nonnucleoside reverse transcrip

262 HIV-1 RNA of at least 1000 copies per mL had drug resistance testing by ultra-deep sequencing, with d

263 indings demonstrate that DBS-based genotypic drug resistance testing for HIV-2 is feasible and can be

264 Dried blood spots (DBS)-based drug resistance testing, widely studied for HIV-1, has n

265 nnoticed in the setting of standard clinical drug resistance testing.

266 n in Senegal and subjected them to genotypic drug resistance testing.

267 id viral load testing, and routine access to drug resistance testing.

268 nd inadequate access to HIV-2 viral load and drug resistance testing.

269 ved the emergence of stable, low-level multi-drug resistance that was both time and concentration dep

270 high mortality in sub-Saharan Africa, while drug resistance threatens current therapies.

271 of MDR leukemias, which typically overcomes drug resistance through distinct mechanisms.

272 aid in the design of new agents to overcome drug resistance to 3TC and ETV.

273 Mechanistically, G1 delays increase drug resistance to cisplatin and paclitaxel by reducing

274 agnostic tool is leading to the profiling of drug resistance to inform clinical practice and treatmen

275 pheral blood mononuclear cells evaluated for drug resistance to non-nucleoside reverse transcriptase

276 vious second-line TB medication exposure, or drug resistance to pyrazinamide, ethambutol, kanamycin,

277 reported adherence to ART and the absence of drug resistance to the current ART regimen.METHODSSample

278 rexpression of Rac1 is associated with multi-drug resistance to the neoadjuvant chemotherapy (NAC).

279 g-resistant cells that overexpressed various drug-resistance transporters were collaterally sensitive

280 uberculosis we found no evidence of acquired drug resistance, underscoring the safety of rifampin mon

281 ical disciplines to address the challenge of drug resistance using a combination of interdisciplinary

282 s common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved.

283 ses and 19 new cases): 16 (43.24%) displayed drug-resistance variants.

284 rable outcomes, and a lower rate of acquired drug resistance versus delamanid-based regimens.

285 the therapy used and develops mechanisms of drug resistance via downstream signalling of key regulat

286 determining the genetic loci responsible for drug resistance, virulence, invasion, growth rate, and t

287 C-MRM-MS analysis and the effect of SMPD1 in drug resistance was assessed by treating DLD-1 cells wit

288 his reservoir in the evolution and spread of drug resistance was explored.

289 tecan/CPT-11) to overcome efflux pump-driven drug resistance was tested.

290 ats (CRISPR) screens to understand endocrine drug resistance, we discovered ARID1A and other SWI/SNF

291 ibitor of influenza to combat the problem of drug resistance, we previously identified the highly con

292 Rates of acquired drug resistance were significantly higher among patients

293 g cancer (NSCLC) patients inevitably develop drug resistance when treated with EGFR tyrosine kinase i

294 t through a process called adhesion-mediated drug resistance, which depends on ALL cell adhesion to t

295 other Mrr1-regulated genes causing increased drug resistance, which may contribute to some instances

296 Associations of drug resistance with sex, age, treatment history, plasma

297 ouse models, overcoming common mechanisms of drug resistance with the potential to elicit fewer toxic

298 ses on recent advances on the role of TME in drug resistance, with a particular focus on the ongoing

299 ive from transcriptional rewiring, promoting drug resistance without concomitant reductions in pathog

300 trimoxazole, and chloramphenicol), extensive drug resistance (XDR) (MDR plus non-susceptible to fluor